4882.T JPX
Perseus Proteomics Inc.
1W: -5.8%
1M: +11.8%
3M: +1.3%
YTD: -32.4%
1Y: -60.3%
3Y: -42.3%
5Y: -79.9%
¥166.00 ($1.05)
+5.00 (+3.11%)
Weekly Expected Move ±7.8%
¥136
¥148
¥161
¥174
¥186
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$120M
+19.9% ▲
5Y CAGR: +7.2%
Gross Profit
$104M
+18.7% ▲
5Y CAGR: +5.7%
Operating Income
-$830M
+7.3% ▲
Net Income
-$905M
+18.1% ▲
EPS (Diluted)
$-63.41
+32.3% ▲
EBITDA
-$899M
-0.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $68M | $72M | $94M | $100M | $120M |
| YoY Growth | -20.1% | +5.9% | +31.0% | +6.6% | +19.9% |
| Cost of Revenue | $4M | $4M | $8M | $13M | $16M |
| Gross Profit | $64M | $68M | $87M | $88M | $104M |
| Gross Margin | 94.3% | 94.2% | 91.9% | 87.3% | 86.4% |
| R&D Expenses | $313M | $308M | $494M | $616M | $595M |
| SG&A Expenses | $162M | $231M | $290M | $366M | $336M |
| Operating Expenses | $476M | $540M | $784M | $982M | $934M |
| Operating Income | -$412M | -$472M | -$698M | -$895M | -$830M |
| Operating Margin | -606.0% | -656.4% | -740.7% | -891.1% | -689.3% |
| Interest Expense | $0 | $0 | $0 | $6M | $0 |
| Income Before Tax | -$411M | -$597M | -$785M | -$1.1B | -$902M |
| Tax Expense | $2M | $2M | $2M | $2M | $2M |
| Net Income | -$413M | -$599M | -$787M | -$1.1B | -$905M |
| Net Margin | -608.1% | -832.8% | -835.4% | -1100.0% | -751.7% |
| EPS (Diluted) | $-59.03 | $-54.47 | $-66.93 | $-93.69 | $-63.41 |
| EBITDA | -$411M | -$471M | -$692M | -$892M | -$899M |
| Shares Outstanding | 7M | 11M | 12M | 12M | 14M |